1027 / 1851
Conclusion (CMT in Stage III)
Current standard regimens remain Carbo-tax and Cis-etoposide
Testing of
targeted agents
in appropriate populations is long
overdue
– no clear indication to date
Promising
immune-therapy
approaches are
under investigation
Prognostic and predictive factors are needed